Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Amarasekara, Dulshara Sachini ^a   Yu, Jiyeon ^a   Rho, Jaerang ^a  

^a Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ADENOSINE TRIPHOSPHATASE; ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BONE DESTRUCTION; BONE REMODELING; CROHN DISEASE; DENDRITIC CELL; FIBROBLAST; HUMAN; INFLAMMATORY AUTOIMMUNE DISEASE; MACROPHAGE; MEDLINE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 TH2 BALANCE; TH17 CELL; ULCERATIVE COLITIS; ANIMAL; BONE DENSITY; IMMUNOLOGY; INFLAMMATION; OSTEOCLAST;

ANIMALS; AUTOIMMUNE DISEASES; BONE DENSITY; BONE REMODELING; BONE RESORPTION; CYTOKINES; HUMANS; INFLAMMATION; OSTEOBLASTS; OSTEOCLASTS;

EID: 84929649404     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/832127     Document Type: Review

References (157)

1. M. C. Walsh, N. Kim, Y. Kadono et al., "Osteoimmunology: interplay between the immune system and bone metabolism," Annual Review of Immunology, vol. 24, pp. 33-63, 2006.
2. X. Feng and J. M. McDonald, "Disorders of bone remodeling," Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 121-145, 2011.
3. J. Rho, M. Takami, and Y. Choi, "Osteoimmunology: interactions of the immune and skeletal systems," Molecules and Cells, vol. 17, no. 1, pp. 1-9, 2004.
4. H. Takayanagi, "Osteoimmunology and the effects of the immune system on bone," Nature Reviews Rheumatology, vol. 5, no. 12, pp. 667-676, 2009.
5. S.-I. Harada and G. A. Rodan, "Control of osteoblast function and regulation of bone mass," Nature, vol. 423, no. 6937, pp. 349-355, 2003.
6. P. Ducy, R. Zhang, V. Geoffroy, A. L. Ridall, and G. Karsenty, "Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation," Cell, vol. 89, no. 5, pp. 747-754, 1997.
7. K. Nakashima, X. Zhou, G. Kunkel et al., "The novel zinc finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation," Cell, vol. 108, no. 1, pp. 17-29, 2002.
8. J.-H. Hong, E. S. Hwang, M. T. McManus et al., "TAZ, a transcriptional modulator of mesenchymal stem cell differentiation," Science, vol. 309, no. 5737, pp. 1074-1078, 2005.
9. W. Wang, N. Lian, Y. Ma et al., "Chondrocytic Atf4 regulates osteoblast differentiation and function via Ihh," Development, vol. 139, no. 3, pp. 601-611, 2012.
10. M. Centrella, M. C. Horowitz, J. M. Wozney, and T. L. Mccarthy, "Transforming growth factor-β gene family members and bone," Endocrine Reviews, vol. 15, no. 1, pp. 27-39, 1994.
11. D. Chen, X. Ji, M. A. Harris et al., "Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages," The Journal of Cell Biology, vol. 142, no. 1, pp. 295-305, 1998.
12. T. Gaur, C. J. Lengner, H. Hovhannisyan et al., "Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression," Journal of Biological Chemistry, vol. 280, no. 39, pp. 33132-33140, 2005.
13. Y. Liu, A. D. Berendsen, S. Jia et al., "Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation," Journal of Clinical Investigation, vol. 122, no. 9, pp. 3101-3113, 2012.
14. S. Mathews, R. Bhonde, P. K. Gupta, and S. Totey, "Extracellular matrix protein mediated regulation of the osteoblast differentiation of bone marrow derived human mesenchymal stem cells," Differentiation, vol. 84, no. 2, pp. 185-192, 2012.
15. X. Wang, K. Harimoto, S. Xie, H. Cheng, J. Liu, and Z. Wang, "Matrix protein biglycan induces osteoblast differentiation through extracellular signal-regulated kinase and smad pathways," Biological and Pharmaceutical Bulletin, vol. 33, no. 11, pp. 1891-1897, 2010.
16. R. L. Jilka, R. S. Weinstein, T. Bellido, A. M. Parfitt, and S. C. Manolagas, "Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines," Journal of Bone and Mineral Research, vol. 13, no. 5, pp. 793-802, 1998.
17. T. Bellido, "Osteocyte-driven bone remodeling," Calcified Tissue International, vol. 94, no. 1, pp. 25-34, 2014.
18. A. R. Wijenayaka, M. Kogawa, H. P. Lim, L. F. Bonewald, D. M. Findlay, and G. J. Atkins, "Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway," PLoS ONE, vol. 6, no. 10, Article ID e25900, 2011.
19. S. L. Teitelbaum and F. P. Ross, "Genetic regulation of osteoclast development and function," Nature Reviews Genetics, vol. 4, no. 8, pp. 638-649, 2003.
20. N. E. Lane, "Epidemiology, etiology, and diagnosis of osteoporosis," The American Journal of Obstetrics and Gynecology, vol. 194, no. 2, pp. S3-S11, 2006.
21. K. Redlich and J. S. Smolen, "Inflammatory bone loss: pathogenesis and therapeutic intervention," Nature Reviews Drug Discovery, vol. 11, no. 3, pp. 234-250, 2012.
22. C. Roux, "Osteoporosis in inflammatory joint diseases," Osteoporosis International, vol. 22, no. 2, pp. 421-433, 2011.
23. M.-C. Boissier, "Cell and cytokine imbalances in rheumatoid synovitis," Joint Bone Spine, vol. 78, no. 3, pp. 230-234, 2011.
24. J. J. O'Shea, A. Ma, and P. Lipsky, "Cytokines and autoimmunity," Nature Reviews Immunology, vol. 2, no. 1, pp. 37-45, 2002.
25. H.-F. Pan, X.-P. Li, S. G. Zheng, and D.-Q. Ye, "Emerging role of interleukin-22 in autoimmune diseases," Cytokine and Growth Factor Reviews, vol. 24, no. 1, pp. 51-57, 2013.
26. M. Aringer and J. S. Smolen, "The role of tumor necrosis factor-alpha in systemic lupus erythematosus," Arthritis Research and Therapy, vol. 10, article 202, 2008.
27. T. Ciucci, L. Ibáñez, A. Boucoiran et al., "Bone marrow Th17 TNFα cells induce osteoclast differentiation, and link bone destruction to IBD," Gut, 2014.
28. G. Eilertsen, C. Nikolaisen, A. Becker-Merok, and J. C. Nossent, "Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus," Lupus, vol. 20, no. 6, pp. 607-613, 2011.
29. M. Linker-Israeli, R. J. Deans, D. J. Wallace, J. Prehn, T. Ozeri-Chen, and J. R. Klinenberg, "Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis," Journal of Immunology, vol. 147, no. 1, pp. 117-123, 1991.
30. Y. Mei, F. Pan, J. Gao et al., "Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis," Clinical Rheumatology, vol. 30, no. 2, pp. 269-273, 2011.
31. K. D. Moudgil and D. Choubey, "Cytokines in autoimmunity: role in induction, regulation, and treatment," Journal of Interferon and Cytokine Research, vol. 31, no. 10, pp. 695-703, 2011.
32. S. K. Sharma, S. Ahmad, and S. K. Sharma, "Serum IL-6 level as a marker of disease activity in ankylosing spondylitis patients with pure axial involvement," Indian Journal of Rheumatology, vol. 9, no. 3, pp. 115-119, 2014.
33. J. A. Fischer, A. J. Hueber, S. Wilson et al., "Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody," Arthritis & Rheumatology, vol. 67, no. 1, pp. 51-62, 2015.
34. C.-C. Chao, S.-J. Chen, I. E. Adamopoulos et al., "Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis," Autoimmunity, vol. 44, no. 3, pp. 243-252, 2011.
35. D. Hürlimann, A. Forster, G. Noll et al., "Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis," Circulation, vol. 106, no. 17, pp. 2184-2187, 2002.
36. Y. Shirota, C. Yarboro, R. Fischer, T.-H. Pham, P. Lipsky, and G. G. Illei, "Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus," Annals of the Rheumatic Diseases, vol. 72, no. 1, pp. 118-128, 2013.
37. J. D. Whalen, E. L. Lechman, C. A. Carlos et al., "Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws," Journal of Immunology, vol. 162, no. 6, pp. 3625-3632, 1999.
38. R. Hardy and M. S. Cooper, "Bone loss in inflammatory disorders," Journal of Endocrinology, vol. 201, no. 3, pp. 309-320, 2009.
39. M. Vis, M. Güler-Yüksel, and W. F. Lems, "Can bone loss in rheumatoid arthritis be prevented?" Osteoporosis International, vol. 24, no. 10, pp. 2541-2553, 2013.
40. D. Vosse and K. de Vlam, "Osteoporosis in rheumatoid arthritis and ankylosing spondylitis," Clinical and Experimental Rheumatology, vol. 27, no. 4, pp. S62-S67, 2009.
41. T. Dimitroulas, S. N. Nikas, P. Trontzas, and G. D. Kitas, "Biologic therapies and systemic bone loss in rheumatoid arthritis," Autoimmunity Reviews, vol. 12, no. 10, pp. 958-966, 2013.
42. E. Lubberts, L. van den Bersselaar, B. Oppers-Walgreen et al., "IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance1," The Journal of Immunology, vol. 170, no. 5, pp. 2655-2662, 2003.
43. E. M. Gravallese, C. Manning, A. Tsay et al., "Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor," Arthritis & Rheumatism, vol. 43, no. 2, pp. 250-258, 2000.
44. Y. Shigeyama, T. Pap, P. Kunzler, B. R. Simmen, R. E. Gay, and S. Gay, "Expression of osteoclast differentiation factor in rheumatoid arthritis," Arthritis & Rheumatism, vol. 43, no. 11, pp. 2523-2530, 2000.
45. M. Stolina, S. Adamu, M. Ominsky et al., "RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis," Journal of Bone and Mineral Research, vol. 20, no. 10, pp. 1756-1765, 2005.
46. S. Kotake, N. Udagawa, N. Takahashi et al., "IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis," The Journal of Clinical Investigation, vol. 103, no. 9, pp. 1345-1352, 1999.
47. K. Redlich, S. Hayer, A. Maier et al., "Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin," Arthritis and Rheumatism, vol. 46, no. 3, pp. 785-792, 2002.
48. J. Zwerina, K. Redlich, K. Polzer et al., "TNF-induced structural joint damage is mediated by IL-1," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 28, pp. 11742-11747, 2007.
49. J. Lam, S. Takeshita, J. E. Barker, O. Kanagawa, F. P. Ross, and S. L. Teitelbaum, "TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand," The Journal of Clinical Investigation, vol. 106, no. 12, pp. 1481-1488, 2000.
50. G. Toraldo, C. Roggia, W.-P. Qian, R. Pacific, and M. N. Weitzmann, "IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor κB ligand and tumor necrosis factor α from T cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 1, pp. 125-130, 2003.
51. S. Wei, H. Kitaura, P. Zhou, F. P. Ross, and S. L. Teitelbaum, "IL-1 mediates TNF-induced osteoclastogenesis," The Journal of Clinical Investigation, vol. 115, no. 2, pp. 282-290, 2005.
52. M. Hashizume, N. Hayakawa, and M. Mihara, "IL-6 transsignalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17," Rheumatology, vol. 47, no. 11, pp. 1635-1640, 2008.
53. P. D. Katsikis, C.-Q. Chu, F. M. Brennan, R. N. Maini, and M. Feldmann, "Immunoregulatory role of interleukin 10 in rheumatoid arthritis," The Journal of Experimental Medicine, vol. 179, no. 5, pp. 1517-1527, 1994.
54. P. Miossec, "Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy," Arthritis & Rheumatism, vol. 48, no. 3, pp. 594-601, 2003.
55. J. A. G. van Roon, F. P. J. G. Lafeber, and J. W. J. Bijlsma, "Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis," Arthritis & Rheumatism, vol. 44, no. 1, pp. 3-12, 2001.
56. H. Matsuno, K. Yudoh, R. Katayama et al., "The role of TNF-α in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera," Rheumatology, vol. 41, no. 3, pp. 329-337, 2002.
57. Y.-H. Zhang, A. Heulsmann, M. M. Tondravi, A. Mukherjee, and Y. Abu-Amer, "Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways," The Journal of Biological Chemistry, vol. 276, no. 1, pp. 563-568, 2001.
58. S. Herman, G. Kroenke, R. Mueller, J. Zerina, K. Redlich, and G. Schett, "OSCAR, a key co-stimulation molecule for osteoclasts, is induced in patients with rheumatoid arthritis," Bone, vol. 43, supplement 1, p. S80, 2008.
59. D. A. Glass II, P. Bialek, J. D. Ahn et al., "Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation," Developmental Cell, vol. 8, no. 5, pp. 751-764, 2005.
60. D. Diarra, M. Stolina, K. Polzer et al., "Dickkopf-1 is a master regulator of joint remodeling," Nature Medicine, vol. 13, no. 2, pp. 156-163, 2007.
61. B. Mao, W. Wu, Y. Li et al., "LDL-receptor-related protein 6 is a receptor for Dickkopf proteins," Nature, vol. 411, no. 6835, pp. 321-325, 2001.
62. D. Daoussis and A. P. Andonopoulos, "The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling?" Seminars in Arthritis and Rheumatism, vol. 41, no. 2, pp. 170-177, 2011.
63. M. Tsukasaki, A. Yamada, D. Suzuki et al., "Expression of POEM, a positive regulator of osteoblast differentiation, is suppressed by TNF-α," Biochemical and Biophysical Research Communications, vol. 410, no. 4, pp. 766-770, 2011.
64. J. S. Smolen, D. M. F. M. van Der Heijde, E. W. St. Clair et al., "Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial," Arthritis & Rheumatism, vol. 54, no. 3, pp. 702-710, 2006.
65. N. Saidenberg-Kermanac'h, A. Corrado, D. Lemeiter, M. C. Devernejoul, M. C. Boissier, and M. E. Cohen-Solal, "TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis," Bone, vol. 35, no. 5, pp. 1200-1207, 2004.
66. U. Lange, J. Teichmann, U. Müller-Ladner, and J. Strunk, "Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study," Rheumatology, vol. 44, no. 12, pp. 1546-1548, 2005.
67. R. Horai, S. Saijo, H. Tanioka et al., "Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice," The Journal of Experimental Medicine, vol. 191, no. 2, pp. 313-320, 2000.
68. T. Mori, T. Miyamoto, H. Yoshida et al., "IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis," International Immunology, vol. 23, no. 11, pp. 701-712, 2011.
69. D. R. Haynes, T. N. Crotti, M. Loric, G. I. Bain, G. J. Atkins, and D. M. Findlay, "Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritis joint," Rheumatology, vol. 40, no. 6, pp. 623-630, 2001.
70. B. Le Goff, F. Blanchard, J.-M. Berthelot, D. Heymann, and Y. Maugars, "Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis," Joint Bone Spine, vol. 77, no. 3, pp. 201-205, 2010.
71. P. K. K. Wong, J. M. W. Quinn, N. A. Sims, A. Van Nieuwenhuijze, I. K. Campbell, and I. P. Wicks, "Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis," Arthritis and Rheumatism, vol. 54, no. 1, pp. 158-168, 2006.
72. J. S. Smolen, A. Beaulieu, A. Rubbert-Roth et al., "Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION Study): a double-blind, placebo-controlled, randomised trial," The Lancet, vol. 371, no. 9617, pp. 987-997, 2008.
73. Y. Tanaka, T. Takeuchi, K. Amanoetal., "Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors," Modern Rheumatology, vol. 24, no. 3, pp. 399-404, 2014.
74. T. Miyamoto, T. Mori, A. Yoshimura, and T. Toyama, "STAT3 is critical to promote inflammatory cytokines and RANKL expression in inflammatory arthritis," Arthritis Research & Therapy, vol. 14, supplement 1, p. P43, 2012.
75. M. J. Ruddy, F. Shen, J. B. Smith, A. Sharma, and S. L. Gaffen, "Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment," Journal of Leukocyte Biology, vol. 76, no. 1, pp. 135-144, 2004.
76. F. Fossiez, O. Djossou, P. Chomarat et al., "T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines," The Journal of Experimental Medicine, vol. 183, no. 6, pp. 2593-2603, 1996.
77. S. Shahrara, S. R. Pickens, A. Dorfleutner, and R. M. Pope, "IL-17 induces monocyte migration in rheumatoid arthritis," Journal of Immunology, vol. 182, no. 6, pp. 3884-3891, 2009.
78. M. Chabaud, F. Fossiez, J.-L. Taupin, and P. Miossec, "Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines," Journal of Immunology, vol. 161, no. 1, pp. 409-414, 1998.
79. M. Chabaud, G. Page, and P. Miossec, "Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines," Journal of Immunology, vol. 167, no. 10, pp. 6015-6020, 2001.
80. Y. Katz, O. Nadiv, and Y. Beer, "Interleukin-17 enhances tumor necrosis factor α-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a 'fine-tuning cytokine' in inflammation processes," Arthritis & Rheumatism, vol. 44, no. 9, pp. 2176-2184, 2001.
81. S.-Y. Hwang, J.-Y. Kim, K.-W. Kim et al., "IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-κB- and PI3-kinase/Akt-dependent pathways," Arthritis Research & Therapy, vol. 6, no. 2, pp. R120-R128, 2004.
82. F. Shen and S. L. Gaffen, "Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy," Cytokine, vol. 41, no. 2, pp. 92-104, 2008.
83. M. Chabaud, P. Garnero, J.-M. Dayer, P.-A. Guerne, F. Fossiez, and P. Miossec, "Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis," Cytokine, vol. 12, no. 7, pp. 1092-1099, 2000.
84. P. J. Koshy, N. Henderson, C. Logan, P. F. Life, T. E. Cawston, and A. D. Rowan, "Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines," Annals of the Rheumatic Diseases, vol. 61, no. 8, pp. 704-713, 2002.
85. A. LeGrand, B. Fermor, C. Fink et al., "Interleukin-1, tumor necrosis factor α, andinterleukin-17 synergisticallyup-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci," Arthritis & Rheumatism, vol. 44, no. 9, pp. 2078-2083, 2001.
86. D. V. Jovanovic, J. Martel-Pelletier, J. A. DiBattista et al., "Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis," Arthritis & Rheumatology, vol. 43, pp. 1134-1144, 2000.
87. K. S. A. Sato, A. Suematsu, K. Okamoto et al., "Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction," The Journal of Experimental Medicine, vol. 203, no. 12, pp. 2673-2682, 2006.
88. T. Yago, Y. Nanke, N. Ichikawa et al., "IL-17 induces osteo from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-α antibody: a novel mechanism of osteoclastogenesis by IL-17," Journal of Cellular Biochemistry, vol. 108, no. 4, pp. 947-955, 2009.
89. S. Kitami, H. Tanaka, T. Kawato et al., "IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells," Biochimie, vol. 92, no. 4, pp. 398-404, 2010.
90. H. Huang, H. J. Kim, E.-J. Chang et al., "IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling," Cell Death and Differentiation, vol. 16, no. 10, pp. 1332-1343, 2009.
91. J. Kikuta, Y. Wada, T. Kowada et al., "Dynamic visualization of RANKL and Th17-mediated osteoclast function," The Journal of Clinical Investigation, vol. 123, no. 2, pp. 866-873, 2013.
92. M. I. Koenders, E. Lubberts, B. Oppers-Walgreen et al., "Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1," The American Journal of Pathology, vol. 167, no. 1, pp. 141-149, 2005.
93. K. A. Bush, K. M. Farmer, J. S. Walker, and B. W. Kirkham, "Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein," Arthritis and Rheumatism, vol. 46, no. 3, pp. 802-805, 2002.
94. M. Chabaud and P. Miossec, "The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model," Arthritis & Rheumatism, vol. 44, no. 6, pp. 1293-1303, 2001.
95. T. Pham, "Pathophysiology of ankylosing spondylitis: what's new?" Joint Bone Spine, vol. 75, no. 6, pp. 656-660, 2008.
96. G. Schett and J.-P. David, "The multiple faces of autoimmune-mediated bone loss," Nature Reviews Endocrinology, vol. 6, no. 12, pp. 698-706, 2010.
97. N. Davey-Ranasinghe and A. Deodhar, "Osteoporosis and vertebral fractures in ankylosing spondylitis," Current Opinion in Rheumatology, vol. 25, no. 4, pp. 509-516, 2013.
98. B. Osta, G. Benedetti, and P. Miossec, "Classical and paradoxical effects of TNF-α on bone homeostasis," Frontiers in Immunology, vol. 5, article 48, 2014.
99. X. Baraliakos, H. Haibel, J. Listing, J. Sieper, and J. Braun, "Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis," Annals of the Rheumatic Diseases, vol. 73, no. 4, pp. 710-715, 2014.
100. R. J. François, L. Neure, J. Sieper, and J. Braun, "Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor αalpha in two patients with early disease and transforming growth factor beta in three more advanced cases," Annals of the Rheumatic Diseases, vol. 65, no. 6, pp. 713-720, 2006.
101. J. Sieper, J. Braun, J. Kay et al., "Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)," Annals of the Rheumatic Diseases, 2014.
102. J. Sieper, B. Porter-Brown, L. Thompson, O. Harari, and M. Dougados, "Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials," Annals of the Rheumatic Diseases, vol. 73, no. 1, pp. 95-100, 2014.
103. H. Shen, J. C. Goodall, and J. S. Hill Gaston, "Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis," Arthritis and Rheumatism, vol. 60, no. 6, pp. 1647-1656, 2009.
104. L. Zhang, Y. G. Li, Y. H. Li et al., "Increased frequencies of th22 cells as well as th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis," PLoS ONE, vol. 7, Article ID e31000, 2012.
105. D. Baeten, X. Baraliakos, J. Braun et al., "Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial," The Lancet, vol. 382, no. 9906, pp. 1705-1713, 2013.
106. J. F. Zambrano-Zaragoza, J. M. Agraz-Cibrian, C. González-Reyes, M. D. J. Durán-Avelar, and N. Vibanco-Pérez, "Ankylosing spondylitis: from cells to genes," International Journal of Inflammation, vol. 2013, Article ID 501653, 16 pages, 2013.
107. D. Stupphann, M. Rauner, D. Krenbek et al., "Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis," Rheumatology International, vol. 28, no. 10, pp. 987-993, 2008.
108. C. H. Im, E. H. Kang, J. Y. Ki et al., "Receptor activator of nuclear factor kappa B ligand-mediated osteoclastogenesis is elevated in ankylosing spondylitis," Clinical and Experimental Rheumatology, vol. 27, no. 4, pp. 620-625, 2009.
109. A. Leibbrandt and J. M. Penninger, "RANK/RANKL: regulators of immune responses and bone physiology," Annals of the New York Academy of Sciences, vol. 1143, pp. 123-150, 2008.
110. A. Kaser, S. Zeissig, and R. S. Blumberg, "Inflammatory bowel disease," Annual Review of Immunology, vol. 28, pp. 573-621, 2010.
111. K. L. Wallace, L.-B. Zheng, Y. Kanazawa, and D. Q. Shih, "Immunopathology of inflammatory bowel disease," World Journal of Gastroenterology, vol. 20, no. 1, pp. 6-21, 2014.
112. D. Q. Shih, S. R. Targan, and D. McGovern, "Recent advances in IBD pathogenesis: genetics and immunobiology," Current Gastroenterology Reports, vol. 10, no. 6, pp. 568-575, 2008.
113. L. E. Targownik, C. N. Bernstein, and W. D. Leslie, "Inflammatory bowel disease and the risk of osteoporosis and fracture," Maturitas, vol. 76, no. 4, pp. 315-319, 2013.
114. G. Rogler and T. Andus, "Cytokines in inflammatory bowel disease," World Journal of Surgery, vol. 22, no. 4, pp. 382-389, 1998.
115. M. F. Neurath and S. Finotto, "IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer," Cytokine and Growth Factor Reviews, vol. 22, no. 2, pp. 83-89, 2011.
116. H. C. Reinecker, M. Steffen, T. Witthoeft et al., "Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease," Clinical and Experimental Immunology, vol. 94, no. 1, pp. 174-181, 1993.
117. S. G. Veerappan, C. A. O'Morain, J. S. Daly, and B. M. Ryan, "Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease," Alimentary Pharmacology and Therapeutics, vol. 33, no. 12, pp. 1261-1272, 2011.
118. P. Miheller, G. Muzes, K. Rácz et al., "Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy," Inflammatory Bowel Diseases, vol. 13, no. 11, pp. 1379-1384, 2007.
119. N. Franchimont, V. Putzeys, J. Collette et al., "Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease," Alimentary Pharmacology and Therapeutics, vol. 20, no. 6, pp. 607-614, 2004.
120. M. Pazianas, A. D. Rhim, A. M. Weinberg, C. Su, and G. R. Lichtenstein, "The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease," Annals of the New York Academy of Sciences, vol. 1068, no. 1, pp. 543-556, 2006.
121. A. R. Moschen, A. Kaser, B. Enrich et al., "The RANKL/OPG system is activated in inflammatory bowel diseases and relates to the state or bone loss," Gut, vol. 54, no. 4, pp. 479-487, 2005.
122. W. Jiang, J. Su, X. Zhang et al., "Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease," Inflammation Research, vol. 63, no. 11, pp. 943-950, 2014.
123. D. Fina, M. Sarra, M. C. Fantini et al., "Regulation of gut inflammation and Th17 cell response by interleukin-21," Gastroenterology, vol. 134, no. 4, pp. 1038.e2-1048.e2, 2008.
124. G. Monteleone, I. Monteleone, D. Fina et al., "Interleukin-21 enhances T-helper cell type I signaling and interferon-γ production in Crohn's disease," Gastroenterology, vol. 128, no. 3, pp. 687-694, 2005.
125. J. B. Seidelin, G. Rogler, and O. H. Nielsen, "A role for interleukin-33 in TH2-polarized intestinal inflammation," Mucosal Immunology, vol. 4, no. 5, pp. 496-502, 2011.
126. L. R. Lopetuso, S. Chowdhry, and T. T. Pizarro, "Opposing functions of classic and novel IL-1 family members in gut health and disease," Frontiers in Immunology, vol. 4, article181, 2013.
127. G. Palmer, D. Talabot-Ayer, C. Lamacchia et al., "Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis," Arthritis and Rheumatism, vol. 60, no. 3, pp. 738-749, 2009.
128. S. H. Mun, N. Y. Ko, H. S. Kim et al., "Interleukin-33 stimulates formation of functional osteoclasts from human CD14+ monocytes," Cellular and Molecular Life Sciences, vol. 67, no. 22, pp. 3883-3892, 2010.
129. S. Mascheretti, J. Hampe, T. Kühbacher et al., "Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab," Pharmacogenomics Journal, vol. 2, no. 2, pp. 127-136, 2002.
130. P. Rutgeerts, W. J. Sandborn, B. G. Feagan et al., "Infliximab for induction and maintenance therapy for ulcerative colitis," The New England Journal of Medicine, vol. 353, no. 23, pp. 2462-2476, 2005.
131. S. Bank, P. S. Andersen, J. Burisch et al., "Associations between functional polymorphisms in the NFkappaB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease," The Pharmacogenomics Journal, vol. 14, pp. 526-534, 2014.
132. D.-L. Su, Z.-M. Lu, M.-N. Shen, X. Li, and L.-Y. Sun, "Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE," Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 347141, 15 pages, 2012.
133. O. P. Rekvig, C. Putterman, C. Casu et al., "Autoantibodies in lupus: culprits or passive bystanders?" Autoimmunity Reviews, vol. 11, no. 8, pp. 596-603, 2012.
134. C. E. Weckerle, D. Mangale, B. S. Franek et al., "Large-scale analysis of tumor necrosis factor α levels in systemic lupus erythematosus," Arthritis & Rheumatism, vol. 64, no. 9, pp. 2947-2952, 2012.
135. M. Aringer and J. S. Smolen, "Therapeutic blockade of TNF in patients with SLE - Promising or crazy?" Autoimmunity Reviews, vol. 11, no. 5, pp. 321-325, 2012.
136. H.-Y. Chun, J.-W. Chung, H.-A. Kim et al., "Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus," Journal of Clinical Immunology, vol. 27, no. 5, pp. 461-466, 2007.
137. O. Dienz, S. M. Eaton, J. P. Bond et al., "The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells," Journal of Experimental Medicine, vol. 206, no. 1, pp. 69-78, 2009.
138. S. Wan, C. Xia, and L. Morel, "IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions," The Journal of Immunology, vol. 178, no. 1, pp. 271-279, 2007.
139. T. Tanaka, M. Narazaki, and T. Kishimoto, "Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases," FEBS Letters, vol. 585, no. 23, pp. 3699-3709, 2011.
140. A. Doreau, A. Belot, J. Bastid et al., "Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus," Nature Immunology, vol. 10, no. 7, pp. 778-785, 2009.
141. H.-C. Hsu, P. Yang, J. Wang et al., "Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice," Nature Immunology, vol. 9, no. 2, pp. 166-175, 2008.
142. C. Albanesi, A. Cavani, and G. Girolomoni, "IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-γ and TNF-α," Journal of Immunology, vol. 162, no. 1, pp. 494-502, 1999.
143. C. K. Wong, L. C. W. Lit, L. S. Tam, E. K. M. Li, P. T. Y. Wong, and C. W. K. Lam, "Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity," Clinical Immunology, vol. 127, no. 3, pp. 385-393, 2008.
144. K. Shah, W.-W. Lee, S.-H. Lee et al., "Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus," Arthritis Research and Therapy, vol. 12, no. 2, article R53, 2010.
145. J. C. Martin, D. L. Baeten, and R. Josien, "Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus," Clinical Immunology, vol. 154, no. 1, pp. 1-12, 2014.
146. J. J. Hooks, H. M. Moutsopoulos, S. A. Geis, N. I. Stahl, J. L. Decker, and A. L. Notkins, "Immune interferon in the circulation of patients with autoimmune disease," New England Journal of Medicine, vol. 301, no. 1, pp. 5-8, 1979.
147. M. K. Crow and K. A. Kirou, "Interferon-alpha in systemic lupus erythematosus," Current Opinion in Rheumatology, vol. 16, no. 5, pp. 541-547, 2004.
148. J. Banchereau and V. Pascual, "Type I interferon in systemic lupus erythematosus and other autoimmune diseases," Immunity, vol. 25, no. 3, pp. 383-392, 2006.
149. Z. Brkic, O. B. Corneth, C. G. van Helden-Meeuwsen et al., "T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?" Arthritis Research & Therapy, vol. 16, article R62, 2014.
150. Z. Liu, R. Bethunaickan, W. Huang et al., "Interferon-α accelerates murine systemic lupus erythematosus in a T cell-dependent manner," Arthritis and Rheumatism, vol. 63, no. 1, pp. 219-229, 2011.
151. K. A. Kirou and E. Gkrouzman, "Anti-interferon alpha treatment in SLE," Clinical Immunology, vol. 148, no. 3, pp. 303-312, 2013.
152. I. E. M. Bultink, "Osteoporosis and fractures in systemic lupus erythematosus," Arthritis Care and Research, vol. 64, no. 1, pp. 2-8, 2012.
153. Y. Tang, H. Xie, J. Chen et al., "Activated NF-κB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating smad signaling," Stem Cells and Development, vol. 22, no. 4, pp. 668-678, 2013.
154. E. Svenungsson, I. Gunnarsson, G.-Z. Fei, I. E. Lundberg, L. Klareskog, and J. Frostegård, "Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor α/tumor necrosis factor receptor system in systemic lupus erythematosus," Arthritis & Rheumatism, vol. 48, no. 9, pp. 2533-2540, 2003.
155. E. Svenungsson, G.-Z. Fei, K. Jensen-Urstad, U. de Faire, A. Hamsten, and J. Frostegård, "TNF-α: A link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease," Lupus, vol. 12, no. 6, pp. 454-461, 2003.
156. L. S. Graham, F. Parhami, Y. Tintut, C. M. R. Kitchen, L. L. Demer, and R. B. Effros, "Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss," Clinical Immunology, vol. 133, no. 2, pp. 265-275, 2009.
157. F. Shen, M. J. Ruddy, P. Plamondon, and S. L. Gaffen, "Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17- and TNF-α-induced genes in bone cells," Journal of Leukocyte Biology, vol. 77, no. 3, pp. 388-399, 2005.